Cervical Cancer Pipeline Expands as 70+ Pharma Leaders Advance 70+ Novel Therapies, Reports DelveInsight | Merck, AstraZeneca, Advaxis, Akeso, GlaxoSmithKline, Genmab

DelveInsight's "Cervical Cancer - Pipeline Insight, 2026" report provides comprehensive insights about 70+ companies developing several pipeline drugs in the Cervical Cancer pipeline landscape. It covers the Cervical Cancer pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Cervical Cancer treatment landscape. Learn more about the evolving Cervical Cancer pipeline today @ https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Cervical Cancer Pipeline Report

• In February 2026, Merck Sharp & Dohme LLC conducted a study to assess the efficacy and safety of pembrolizumab (MK-3475) plus platinum-based chemotherapy compared to placebo in adult women with cervical cancer.
• In April 2026, analysis of filings from Genmab, Merck, Regeneron, and AstraZeneca identified anti-TF ADCs, PD-1/PD-L1 checkpoint inhibitors, and HER2-targeted combinations as central pillars reshaping the cervical cancer drug pipeline.
• Globally, cervical cancer remains the fourth most common cancer in women, with 2022 estimates reporting approximately 662,301 new cases and 348,874 deaths, predominantly affecting low- and middle-income countries.
• Axalimogene filolisbac (ADXS11-001) is currently undergoing Phase III evaluation as an adjuvant treatment for high-risk cervical cancer following chemoradiation.
• In September 2020, the NMPA of China officially accepted the new drug application for the world's first-in-class Cadonilimab (AK104), a PD-1/CTLA-4 bi-specific antibody, for treating relapsed or metastatic cervical cancer.
• The leading Cervical Cancer companies include Merck Sharp & Dohme, AstraZeneca, Advaxis, Akeso, GlaxoSmithKline, Regeneron Pharmaceuticals, and others.
• Promising Cervical Cancer therapies in development include Imfinzi (durvalumab), dostarlimab, HLX10, and Cadonilimab, spanning monoclonal antibodies, bi-specific antibodies, and antibody-drug conjugates (ADCs).

Download for updates and the latest revolution in Cervical Cancer care @ https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Cervical Cancer Emerging Drugs Profile

• Axalimogene filolisbac: Advaxis
Axalimogene filolisbac (ADXS11-001) is an HPV-targeted cancer vaccine developed by Advaxis. It is administered intravenously and is designed for the treatment of persistent, recurrent, or metastatic cervical cancer in patients who progress beyond first-line therapy. Currently, it is in a Phase III study as an adjuvant treatment for high-risk patients following chemoradiation.

• Imfinzi (durvalumab): AstraZeneca
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks its interaction with PD-1 and CD80, countering the tumor's immune-evading tactics. While already established as a standard of care in other oncology indications, it is currently in Phase III clinical trial evaluation specifically for the treatment of locally advanced cervical cancer.

• Cadonilimab (AK104): Akeso
Cadonilimab is a first-in-class PD-1/CTLA-4 bi-specific antibody designed to achieve better efficacy and safety than combination therapy of separate PD-1 and CTLA-4 inhibitors. Preliminary research has demonstrated a promising safety profile and lower toxicity. Following regulatory acceptance in China, it continues to be a significant pipeline asset for relapsed or metastatic cervical cancer.

For more information on the Cervical Cancer Emerging Drugs Profile, download DelveInsight's comprehensive Cervical Cancer Pipeline Insight report @ https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Cervical Cancer Pipeline Report Provides

• Detailed insights about 70+ companies developing 70+ therapies for Cervical Cancer, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage (Phase III) of development for Cervical Cancer treatment.
• Cervical Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cervical Cancer drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations, licensing agreements, and financing details for future advancement of the Cervical Cancer market.

Learn more about Cervical Cancer drug opportunities in our comprehensive Cervical Cancer pipeline report @ https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Cervical Cancer Companies and Competitive Landscape

There are 70+ key companies, including Merck Sharp & Dohme, AstraZeneca, Advaxis, Akeso, GlaxoSmithKline, Regeneron Pharmaceuticals, and others, developing therapies for Cervical Cancer. Several candidates, such as Imfinzi and Axalimogene filolisbac, are currently in the most advanced Phase III stages of clinical evaluation.

DelveInsight's Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Inhalation
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous

Cervical Cancer products have been categorized under various Molecule types such as:

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Discover the latest advancements in Cervical Cancer treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Cervical Cancer Pipeline Report

• Coverage: Global
• Cervical Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Advaxis, Akeso, GlaxoSmithKline, Regeneron, and others.
• Cervical Cancer Therapies: Axalimogene filolisbac, Imfinzi (durvalumab), Cadonilimab (AK104), dostarlimab, and others.
• Cervical Cancer Therapeutic Assessment by Product Type: Mono, Combination
• Cervical Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.